POINT OF NEED
Testing

The best time to perform a blood test is where and when it is needed, not when it is convenient for healthcare systems.

Patients need to KNOW NOW

Screening, diagnosis and monitoring being done at the point of care has become a familiar concept. It means that a patient needs to get to where the care is given – usually a hospital or clinic. This neglects a fundamental truth at the heart of diagnostics: people’s lives revolve around their results, not the limitations of testing equipment.
They want the ability to KNOW NOW.

Now more than ever, patients want to be active participants in their own healthcare. Evidence shows that when they are involved, decisions, health outcomes and resource allocations are improved.1 By combining a revolutionary lab-on-a-chip* with a smartphone, dianax will create a step change in diagnostics. By allowing clinical tests to happen exactly when and where they’re needed, and with no more unnecessary trips to the doctor or hospital, dianax will give patients the freedom and peace of mind they want and need. dianax will literally put laboratory testing at patients’ fingertips.

Every diabetic needs a device like this to monitor their own HbA1c levels in order to immediately take action with their diabetes control

Patient,

South Africa

Physicians need to KNOW NOW

Placing patients and their needs at the heart of technological innovation is only part of the story. It’s the physician’s job to interpret the test results and make informed clinical decisions as efficiently and effectively as possible. They need immediacy, accuracy, reliability and affordability. Bringing diagnostics to the POINT OF NEED means physicians can determine the best course of action for a patient in real time. That applies whether they are based in a hospital, primary care facility, outpatient clinic, ambulance, community pharmacy or implementing a mobile screening program anywhere in the world. At dianax our goal is to empower both patients and physicians, so they are better equipped to tackle a chronic condition like diabetes or anemia in partnership. Together they will prevent, detect and monitor the disease more effectively without unnecessary delays.

The ability to prescribe HbA1c tests and receive the results remotely could have an enormous effect, not only on patients’ quality of life but how diabetes outcomes are monitored entirely […] your device seemed to be offering something revolutionary and it provides a solution to a problem we have been aware of for a long time

Diabetes medical device distributor,

UK

A case in point … Diabetes

One of the biggest global health threats of our time, affecting over 400 million adults with nearly one in two unaware that they have the condition2

A

Current reality:

A1c levels – the gold-standard measure in diabetes care – can only be accurately analyzed by a conventional laboratory test, which delays results. Many commercially available A1c point of care testing devices are prone to test-related variability, leading to systematic or random negative bias in A1c value.3
The selection of a point of care A1c device should be based on accuracy, precision, ease of use, and price.4

The future:

The benefits of a device used by patients and physicians alike could be three-fold:

  • Undiagnosed diabetic: Readily identified in a physical checkup in a doctor’s office, in in-field emergencies and pre-operative evaluations
  • Pre-diabetic: Able to monitor the impact of lifestyle changes
  • Diabetic: Vital means of checking if patients are meeting their A1c goals over time

The bigger picture

The ability to KNOW NOW has far-reaching benefits which extend beyond individual patients and physicians:
Once commercially available, dianax lab-on-a-chip will…:

Play a vital role in integrating diagnostics in a patient-empowered future

Mobile healthcare becoming mainstream has already been a key driver of decentralization and the transition of treatment from hospital to home.

Augment the environmental shift towards value-based healthcare

Diagnostics digital solutions support the move from a fee-for-service to a more outcome-focused and value-based care model. The more accurate and reliable the diagnostics, the easier it is for healthcare providers to obtain tangible measures of improved patient outcomes (vital for value-based reimbursement).

Help to alleviate the hospital burden

As well as reducing the number of blood samples required through increased accuracy, modern diagnostics can further reduce costs by minimizing subsequent health problems, reducing hospitalization and avoiding unnecessary treatment.

Have a significant impact in rural areas and the developing world where the need is greatest

It may be some way off yet, but we are excited by the potential of our cutting-edge technology in areas of the world where laboratories are often poorly resourced and patients may be deprived of life-saving treatment.

POINT OF NEED

When we refer to the POINT OF NEED instead of point of care, it is a deliberate and defining choice.
We need to change traditional ways of thinking about diagnostics – from something inaccessible, time-consuming and clinical to something that can be done anytime, anywhere, for anyone as a vital part of managing chronic disease over time. 

At dianax, we envisage a world in which patients and physicians are companions in diagnostics. They can both act at their own POINT OF NEED, resulting in improved treatment and patient outcomes. 

It’s only if we KNOW NOW that we can be sure we are providing the right treatment at the right time. 

*Products/devices are under development but not yet approved for use. For investigational use only.

 

  1. The Kings Fund https://www.kingsfund.org.uk/publications/people-control-their-own-health-and-care [Accessed 10 Dec 2017]
  2. International Diabetes Federation Diabetes Atlas - 8th Edition http://www.diabetesatlas.org/key-messages.html [Accessed 10 Dec 2017]
  3. Hirst J, et al. Clin Chem Lab Med 2017; 55(2):167–180 https://www.degruyter.com/downloadpdf/j/cclm.2017.55.issue-2/cclm-2016-0303/cclm-2016-0303.pdf
    [Accessed 10 Dec 2017]
  4. Whitley HP, et al. Diabetes Spectr. 2015;28(3):201–208 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536639/ [Accessed 10 Dec 2017]